Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.
Sarah P. Blagden(Churchill Hospital), Tarek Meniawy(St John of God Subiaco Hospital), Anne Hamilton(Royal Women's Hospital), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Michelle DeSilvio(Newark Beth Israel Medical Center), Jeffrey C. Goh(Royal Brisbane and Women's Hospital), Hani Gabra(Royal Children's Hospital), Dany Habr, Linda Mileshkin(Peter MacCallum Cancer Centre), Agnieszka Michael(University of Surrey), Alla Sergeevua Lisyanskaya(City Clinical Oncology Center), Shelby D. Gainer, Prashanth Gopalakrishna(Novartis (Switzerland)), Shirley Wong(Western Hospital)
Cited by 4
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222